Inventiva, a biopharmaceutical company developing innovative therapies, particularly to treat fibrosis, has appointed Dr Nanna Lüneborg as its Board member, succeeding Mr Philippe Goupit.
With this appointment, Inventiva’s Board of Directors comprises eight directors, including four independent directors.
Nanna Lüneborg is a Principal of Novo Ventures, a leading global life science investor, which participated in the IPO of Inventiva in February 2017. Novo Ventures is part of Novo A/S, the holding and investment company of the Novo Nordisk foundation.
“I am very pleased to be joining Inventiva’s Board of Directors. Inventiva has a promising portfolio of advanced products in fields that are stirring up significant interest in the pharmaceuticals industry. Being able to demonstrate positive results in NASH 1 , systemic sclerosis and MPS VI would constitute a major step forward for millions of patients who are still not receiving effective treatment,” said Dr Lüneborg.